The Kids Research Institute Australia logo
Donate

Discover Prevent Cure

Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia

Despite significant advances, outcomes for children with Down syndrome (DS, trisomy 21) who develop acute lymphoblastic leukemia remain poor. Reports of large DS-ALL cohorts have shown that children with DS have inferior event-free survival and overall survival compared to children without DS.

Citation:
Carey-Smith SL, Simad MH, Panchal K, …….. Cheung LC, Kotecha RS, Malinge S. Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia. Haematologica. 2024;109(7):2309-15.

Keywords:
Down syndrome; complications; drug therapy; precursor cell lymphoblastic leukemia-lymphoma; protein-tyrosine kinases; antagonists & inhibitors; Dyrk Kinases

Abstract:
Despite significant advances, outcomes for children with Down syndrome (DS, trisomy 21) who develop acute lymphoblastic leukemia remain poor. Reports of large DS-ALL cohorts have shown that children with DS have inferior event-free survival and overall survival compared to children without DS.